21,907 Shares in TG Therapeutics, Inc. $TGTX Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the 3rd quarter, Holdings Channel.com reports. The firm bought 21,907 shares of the biopharmaceutical company’s stock, valued at approximately $1,222,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of TG Therapeutics during the 2nd quarter worth approximately $1,211,429,000. Bank of America Corp DE grew its holdings in shares of TG Therapeutics by 71.7% in the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after acquiring an additional 610,195 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of TG Therapeutics by 129.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock valued at $36,029,000 after acquiring an additional 612,068 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of TG Therapeutics in the second quarter valued at about $49,472,000. Finally, Wellington Management Group LLP raised its holdings in TG Therapeutics by 697.6% during the second quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock worth $26,276,000 after acquiring an additional 418,300 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $64.51 on Monday. The firm has a 50 day moving average price of $56.69 and a two-hundred day moving average price of $45.33. The company has a quick ratio of 3.75, a current ratio of 4.50 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $9.75 billion, a PE ratio of 97.74, a price-to-earnings-growth ratio of 5.08 and a beta of 1.89. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $68.03.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.36 by ($0.01). TG Therapeutics had a net margin of 11.81% and a return on equity of 18.82%. The firm had revenue of $259.94 million during the quarter, compared to analyst estimates of $245.47 million. During the same period in the previous year, the company posted $2.43 EPS. TG Therapeutics’s revenue for the quarter was up 60.8% compared to the same quarter last year. As a group, analysts predict that TG Therapeutics, Inc. will post 1.10 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the company. B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Weiss Ratings raised TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, November 4th. Zacks Research upgraded TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. Finally, Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $63.00.

View Our Latest Stock Analysis on TG Therapeutics

Insiders Place Their Bets

In related news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the sale, the director directly owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 8.87% of the company’s stock.

TG Therapeutics Profile

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

See Also

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.